354 related articles for article (PubMed ID: 19566111)
21. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Yoshikawa K; Nakazawa Y; Katsuyama Y; Hirabayashi K; Saito S; Shigemura T; Tanaka M; Yanagisawa R; Sakashita K; Koike K
Infection; 2014 Aug; 42(4):639-47. PubMed ID: 24567233
[TBL] [Abstract][Full Text] [Related]
22. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
24. The echinocandins: three useful choices or three too many?
Bal AM
Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
[TBL] [Abstract][Full Text] [Related]
25. Micafungin for the prophylaxis and treatment of Candida infections.
Fritz JM; Brielmaier BD; Dubberke ER
Expert Rev Anti Infect Ther; 2008 Apr; 6(2):153-62. PubMed ID: 18380597
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
Catalán-González M; Carlos Montejo-González J
Rev Iberoam Micol; 2009 Mar; 26(1):23-34. PubMed ID: 19463274
[TBL] [Abstract][Full Text] [Related]
27. The management of Candida infections in preterm neonates and the role of micafungin.
Manzoni P; Benjamin DK; Hope W; Rizzollo S; Del Sordo P; Stronati M; Jacqz-Aigrain E; Castagnola E; Farina D
J Matern Fetal Neonatal Med; 2011 Oct; 24 Suppl 2():24-7. PubMed ID: 21749182
[TBL] [Abstract][Full Text] [Related]
28. Micafungin for the treatment of invasive aspergillosis.
Enoch DA; Idris SF; Aliyu SH; Micallef C; Sule O; Karas JA
J Infect; 2014 Jun; 68(6):507-26. PubMed ID: 24480373
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
30. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
[TBL] [Abstract][Full Text] [Related]
32. Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
[TBL] [Abstract][Full Text] [Related]
33. [Micafungin in pediatric and adolescent patients].
Madero-López L
Rev Iberoam Micol; 2009 Mar; 26(1):62-4. PubMed ID: 19463279
[TBL] [Abstract][Full Text] [Related]
34. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
[TBL] [Abstract][Full Text] [Related]
35. Micafungin: a new echinocandin antifungal.
Joseph JM; Jain R; Danziger LH
Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
[TBL] [Abstract][Full Text] [Related]
36. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
38. [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients].
Pozo-Laderas JC
Rev Iberoam Micol; 2009 Mar; 26(1):69-74. PubMed ID: 19463281
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
40. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
